Verily And iRhythm Agree To Collaborate On Atrial Fibrillation
Executive Summary
Verily Life Sciences and iRhythm Technologies have agreed to co-develop technology for screening, diagnosing and managing patients with atrial fibrillation, combining iRhythm’s artificial intelligence system for diagnosing arrhythmias with Verily’s health data analytics technology.
You may also be interested in...
Cardio Conversations: 'Trials, Trials, Trials!' Volta Has Big Ambitions For AI In EP
In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical, a Marseille-based company applying artificial intelligence to electrophysiology. Volta has raised over €70m and is sponsoring the TAILORED AF trial to show that its software can make atrial fibrillation ablation more effective.
FDA Clears iRhythm’s Afib-Detecting Wearable Running Software Co-Developed By Verily
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.